scFv(HER2)-CD28-41BB-CD3zeta CAR-T Lentivirus

scFv(HER2)-CD28-41BB-CD3ζ CAR-T Lentivirus is a gene-delivery reagent designed to generate T cells with targeted recognition of human epidermal growth factor receptor 2 (HER2/ERBB2). The encoded third-generation chimeric antigen receptor contains an extracellular anti-HER2 single-chain variable fragment (scFv), membrane-anchoring elements, tandem intracellular costimulatory domains from CD28 and 4-1BB (CD137), and the CD3ζ activation domain. The scFv recognizes HER2 on the cell surface independently of major histocompatibility complex presentation. Upon antigen binding, CD3ζ initiates T-cell activation, while CD28 and 4-1BB provide complementary costimulatory signals associated with effector activity, proliferation, survival, and persistence. Lentiviral delivery supports efficient gene transfer and stable CAR expression in transduced T cells, offering a practical platform for investigating how dual costimulation shapes HER2-directed immune responses.

This product is intended for research on HER2-targeted cellular immunotherapy and the functional evaluation of third-generation CAR-T cells. Transduced cells can be studied for CAR expression, antigen-dependent activation, cytotoxicity, cytokine secretion, expansion, survival, memory differentiation, and exhaustion. Comparisons using HER2-high, HER2-low, and HER2-negative target cells can help define antigen-density requirements, selectivity, and possible on-target effects across different expression levels. The resulting CAR-T cells are suitable for appropriately designed studies involving HER2-expressing breast, gastric, ovarian, lung, and other solid-tumor models. The construct also provides a useful benchmark for comparing dual-costimulatory signaling with first-generation CD3ζ-only receptors or second-generation CARs containing either CD28 or 4-1BB. Additional applications include examining repeated antigen exposure, tumor-cell resistance, immune escape, and CAR-T-cell performance within suppressive tumor microenvironments. Its lentiviral format helps streamline exploratory screening, mechanistic studies, and early-stage assessment of combination approaches involving checkpoint inhibitors, targeted agents, cytokines, or other immune-modulating strategies.